Business, energy, technology, markets and global industry news from Business News Today

AmBisome

PharmaDeviceNews AmBisome
Representative image of invasive aspergillosis research as F2G and Shionogi report positive Phase 3 olorofim results, highlighting its potential as a new oral antifungal treatment.
Pharma & Biotech

Olorofim Phase 3 results show fewer kidney complications in patients with invasive aspergillosis

F2G and Shionogi's oral olorofim meets Phase 3 aspergillosis endpoint with fewer kidney adverse events. Explore the results and FDA plans.

Read More
Representative image: Healthcare workers review treatment supplies in a regional clinic as Gilead Sciences and the World Health Organization renew efforts to expand AmBisome access and strengthen visceral leishmaniasis elimination programmes.
Pharma & Biotech

Why Gilead’s visceral leishmaniasis collaboration with WHO matters beyond drug donation

Gilead’s WHO pact targets kala-azar access, but diagnostics, treatment delivery and East Africa execution will decide the impact.

Read More